Literature DB >> 21800414

Inclusion and exclusion criteria for malformations in newborn infants exposed to potential teratogens.

Lewis B Holmes1, Marie-Noel Westgate.   

Abstract

BACKGROUND: The surveillance of newborn infants exposed to potential teratogens often relies on the findings in routine physicians' examinations to identify malformations. Exposed newborn infants can have a wide variety of physical features, including malformations, birth marks, positional deformities, and minor anomalies. The routine physician's findings are not standardized. Some physicians record a wide variety of physical features and others do not. The purpose of this study was to develop criteria and definitions for identifying malformations and for identifying the more common and less severe physical features that would be excluded as not being malformations.
METHODS: The physical features recorded by the examining pediatricians were obtained from a review of the medical records of a consecutive sample of 1000 liveborn and stillborn infants and elective terminations for fetal anomalies.
RESULTS: A malformation, defined as a structural abnormality with surgical, medical or cosmetic importance, was present in 18 (2.8%) of the infants; 222 other recorded features were identified and excluded: malformations attributed to dominant or recessive genes (4) or chromosome abnormalities (6), minor anomalies and normal variations (65), birth marks (110), positional deformities (6), prematurity-related features (5), physiologic findings (4) and findings identified by prenatal ultrasound (but not by the examining pediatrician) (20), functional abnormalities (1) and findings in newborn screening (1).
CONCLUSIONS: Investigators should establish, in advance, the exclusion criteria to be used in programs, such as malformation surveillance programs or pregnancy registries, whose findings are based on a review of the routine examinations in medical records. It is essential that the same criteria be used in evaluating the drug-exposed and the unexposed comparison group.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21800414     DOI: 10.1002/bdra.20842

Source DB:  PubMed          Journal:  Birth Defects Res A Clin Mol Teratol        ISSN: 1542-0752


  17 in total

1.  Exposure to Sodium Valproate during Pregnancy: Facial Features and Signs of Autism.

Authors:  Rachel Stadelmaier; Hanah Nasri; Curtis K Deutsch; Margaret Bauman; Anne Hunt; Christopher J Stodgell; Jane Adams; Lewis B Holmes
Journal:  Birth Defects Res       Date:  2017-06-21       Impact factor: 2.344

2.  First trimester exposure to antiretroviral therapy and risk of birth defects.

Authors:  Kelesitse Phiri; Sonia Hernandez-Diaz; Kate B Dugan; Paige L Williams; Judith A Dudley; Astride Jules; S Todd Callahan; George R Seage; William O Cooper
Journal:  Pediatr Infect Dis J       Date:  2014-07       Impact factor: 2.129

3.  Setting Standards for Pregnancy Registries.

Authors:  Lewis B Holmes
Journal:  Drug Saf       Date:  2018-01       Impact factor: 5.606

Review 4.  Use of real-world evidence from healthcare utilization data to evaluate drug safety during pregnancy.

Authors:  Krista F Huybrechts; Brian T Bateman; Sonia Hernández-Díaz
Journal:  Pharmacoepidemiol Drug Saf       Date:  2019-05-10       Impact factor: 2.890

5.  Assessment of congenital anomalies in infants born to pregnant women enrolled in clinical trials.

Authors:  Sonja A Rasmussen; Sonia Hernandez-Diaz; Omar A Abdul-Rahman; Leyla Sahin; Carey R Petrie; Kim M Keppler-Noreuil; Sharon E Frey; Robin M Mason; Mirjana Nesin; John C Carey
Journal:  Clin Infect Dis       Date:  2014-12-15       Impact factor: 9.079

6.  The Impact of Technology on the Diagnosis of Congenital Malformations.

Authors:  Loreen Straub; Krista F Huybrechts; Brian T Bateman; Helen Mogun; Kathryn J Gray; Lewis B Holmes; Sonia Hernandez-Diaz
Journal:  Am J Epidemiol       Date:  2019-11-01       Impact factor: 4.897

Review 7.  Epidemiologic tools to study the influence of environmental factors on fecundity and pregnancy-related outcomes.

Authors:  Rémy Slama; Ferran Ballester; Maribel Casas; Sylvaine Cordier; Merete Eggesbø; Carmen Iniguez; Mark Nieuwenhuijsen; Claire Philippat; Sylvie Rey; Stéphanie Vandentorren; Martine Vrijheid
Journal:  Epidemiol Rev       Date:  2013-12-20       Impact factor: 6.222

8.  Challenges in Studying Modifiable Risk Factors for Birth Defects.

Authors:  Sarah C Tinker; Suzanne Gilboa; Jennita Reefhuis; Mary M Jenkins; Marcy Schaeffer; Cynthia A Moore
Journal:  Curr Epidemiol Rep       Date:  2015-03

9.  Limited surface examination to evaluate potential teratogens in a resource-limited setting.

Authors:  Lewis B Holmes; Hanah Z Nasri; Anne-Therese Hunt; Rebecca Zash; Roger L Shapiro
Journal:  Birth Defects Res       Date:  2021-03-28       Impact factor: 2.344

10.  Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial.

Authors:  Shahin Lockman; Sean S Brummel; Lauren Ziemba; Lynda Stranix-Chibanda; Katie McCarthy; Anne Coletti; Patrick Jean-Philippe; Ben Johnston; Chelsea Krotje; Lee Fairlie; Risa M Hoffman; Paul E Sax; Sikhulile Moyo; Nahida Chakhtoura; Jeffrey Sa Stringer; Gaerolwe Masheto; Violet Korutaro; Haseena Cassim; Blandina T Mmbaga; Esau João; Sherika Hanley; Lynette Purdue; Lewis B Holmes; Jeremiah D Momper; Roger L Shapiro; Navdeep K Thoofer; James F Rooney; Lisa M Frenkel; K Rivet Amico; Lameck Chinula; Judith Currier
Journal:  Lancet       Date:  2021-04-03       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.